HCW Biologics (HCWB) Competitors $3.45 +0.14 (+4.23%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$3.46 +0.01 (+0.43%) As of 08/22/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCWB vs. DYAI, BDRX, MIRA, NNVC, TENX, JATT, FBLG, NAII, LSTA, and PMNShould you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Dyadic International (DYAI), Biodexa Pharmaceuticals (BDRX), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT), FibroBiologics (FBLG), Natural Alternatives International (NAII), Lisata Therapeutics (LSTA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. HCW Biologics vs. Its Competitors Dyadic International Biodexa Pharmaceuticals MIRA Pharmaceuticals NanoViricides Tenax Therapeutics JATT Acquisition FibroBiologics Natural Alternatives International Lisata Therapeutics Promis Neurosciences Dyadic International (NASDAQ:DYAI) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, DYAI or HCWB? Dyadic International has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Do institutionals & insiders have more ownership in DYAI or HCWB? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 42.7% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, DYAI or HCWB? Dyadic International has higher revenue and earnings than HCW Biologics. Dyadic International is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M8.81-$5.81M-$0.19-4.47HCW Biologics$2.57M2.89-$30.02M-$14.04-0.25 Does the media prefer DYAI or HCWB? In the previous week, HCW Biologics had 5 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for HCW Biologics and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.00 beat HCW Biologics' score of -0.21 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Neutral HCW Biologics Neutral Do analysts recommend DYAI or HCWB? Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 605.88%. HCW Biologics has a consensus price target of $35.00, indicating a potential upside of 914.49%. Given HCW Biologics' higher possible upside, analysts clearly believe HCW Biologics is more favorable than Dyadic International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DYAI or HCWB more profitable? Dyadic International has a net margin of -134.84% compared to HCW Biologics' net margin of -1,368.55%. HCW Biologics' return on equity of 0.00% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-134.84% -355.39% -60.66% HCW Biologics -1,368.55%N/A -40.72% SummaryDyadic International beats HCW Biologics on 8 of the 14 factors compared between the two stocks. Get HCW Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCWB vs. The Competition Export to ExcelMetricHCW BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.43M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.40%4.06%P/E Ratio-0.2521.0031.3026.05Price / Sales2.89209.42389.7889.38Price / CashN/A44.5038.0259.36Price / Book-172.508.129.536.60Net Income-$30.02M-$54.72M$3.26B$265.65M7 Day Performance-15.65%2.62%2.13%2.00%1 Month Performance-19.01%3.25%3.21%0.46%1 Year Performance-81.65%10.82%30.18%18.88% HCW Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCWBHCW Biologics2.1251 of 5 stars$3.45+4.2%$35.00+914.5%-81.6%$7.43M$2.57M-0.2540Earnings ReportAnalyst DowngradeShort Interest ↑DYAIDyadic International2.7781 of 5 stars$0.85+5.0%$6.00+605.9%-41.4%$25.58M$3.49M-4.257Gap UpBDRXBiodexa Pharmaceuticals0.3211 of 5 stars$6.99+1.3%N/AN/A$25.51M$470K0.0020Gap DownMIRAMIRA Pharmaceuticals3.0241 of 5 stars$1.47+3.5%$17.00+1,056.5%-22.7%$24.87MN/A-2.882Analyst UpgradeNNVCNanoViricides0.7239 of 5 stars$1.54flatN/A-23.2%$24.75MN/A-2.1420TENXTenax Therapeutics1.6209 of 5 stars$5.89+0.7%$17.50+197.1%+42.2%$24.44MN/A-2.379JATTJATT AcquisitionN/A$1.41-0.7%N/A-43.7%$24.32MN/A0.003High Trading VolumeFBLGFibroBiologics2.7164 of 5 stars$0.57+3.6%$13.00+2,161.7%-62.7%$24.08MN/A-1.6010Short Interest ↑NAIINatural Alternatives InternationalN/A$3.80+2.6%N/A-23.9%$23.45M$113.80M-2.73290LSTALisata Therapeutics2.5412 of 5 stars$2.62-5.4%$23.50+796.9%-13.7%$22.95M$1M-1.1730Analyst ForecastAnalyst RevisionPMNPromis Neurosciences2.3908 of 5 stars$0.70+11.5%$4.33+519.0%-58.8%$22.88MN/A-14.005 Related Companies and Tools Related Companies Dyadic International Competitors Biodexa Pharmaceuticals Competitors MIRA Pharmaceuticals Competitors NanoViricides Competitors Tenax Therapeutics Competitors JATT Acquisition Competitors FibroBiologics Competitors Natural Alternatives International Competitors Lisata Therapeutics Competitors Promis Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCWB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access